STAMPOUT study to be conducted in METH users when funded

Little Rock, AR - Following the successful completion of Phase 1 clinical safety evaluation for the novel anti-methamphetamine antibody IXT-m200 (ch-mAb7F9), InterveXion has announced plans to continue clinical development of this agent. The STAMPOUT study will be a...

read more

Developing Novel Therapeutics for Addiction

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders.  Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS.  IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT).  We are also developing a novel vaccine (IXT-v100) against methamphetamine.

STAMPOUT study to be conducted in METH users when funded

Little Rock, AR - Following the successful completion of Phase 1 clinical safety evaluation for the novel anti-methamphetamine antibody IXT-m200 (ch-mAb7F9), InterveXion has announced plans to continue clinical development of this agent. The STAMPOUT study will be a...

read more

Developing Novel Therapeutics for Addiction

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders.  Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS.  IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT).  We are also developing a novel vaccine (IXT-v100) against methamphetamine.